Log in

NASDAQ:SIENSientra Stock Price, Forecast & News

$3.96
+0.17 (+4.49 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.76
Now: $3.96
$4.15
50-Day Range
$3.64
MA: $3.96
$4.45
52-Week Range
$1.00
Now: $3.96
$9.71
Volume2.02 million shs
Average Volume1.28 million shs
Market Capitalization$199.24 million
P/E RatioN/A
Dividend YieldN/A
Beta1.48
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, OPUS, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline filled breast implant sizers; and miraDry System, a non-surgical device for the permanent reduction of underarm sweat, odor, and hair of all colors. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
Read More
Sientra logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.47 out of 5 stars


Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SIEN
CUSIPN/A
Phone805-562-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$83.70 million
Book Value$1.65 per share

Profitability

Net Income$-106,820,000.00
Net Margins-134.87%

Miscellaneous

Employees339
Market Cap$199.24 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$3.96
+0.17 (+4.49 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SIEN News and Ratings via Email

Sign-up to receive the latest news and ratings for SIEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Sientra (NASDAQ:SIEN) Frequently Asked Questions

How has Sientra's stock price been impacted by COVID-19?

Sientra's stock was trading at $2.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SIEN shares have increased by 62.3% and is now trading at $3.96.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Sientra?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sientra in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Sientra
.

When is Sientra's next earnings date?

Sientra is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Sientra
.

How were Sientra's earnings last quarter?

Sientra Inc (NASDAQ:SIEN) announced its quarterly earnings data on Monday, August, 10th. The medical instruments supplier reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by $0.23. Sientra had a negative return on equity of 101.94% and a negative net margin of 134.87%.
View Sientra's earnings history
.

What price target have analysts set for SIEN?

6 brokers have issued 12-month price objectives for Sientra's stock. Their forecasts range from $5.00 to $9.00. On average, they expect Sientra's share price to reach $6.80 in the next twelve months. This suggests a possible upside of 71.7% from the stock's current price.
View analysts' price targets for Sientra
.

Has Sientra been receiving favorable news coverage?

Headlines about SIEN stock have trended neutral recently, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sientra earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about Sientra
.

Are investors shorting Sientra?

Sientra saw a decrease in short interest in June. As of June 15th, there was short interest totaling 4,410,000 shares, a decrease of 18.5% from the May 31st total of 5,410,000 shares. Based on an average trading volume of 1,870,000 shares, the short-interest ratio is currently 2.4 days. Approximately 10.3% of the company's stock are sold short.
View Sientra's Short Interest
.

Who are some of Sientra's key competitors?

What other stocks do shareholders of Sientra own?

Who are Sientra's key executives?

Sientra's management team includes the following people:
  • Mr. Jeffrey M. Nugent, Chairman & CEO (Age 73, Pay $1.92M)
  • Mr. Paul Sean Little, CFO, Sr. VP & Treasurer (Age 55, Pay $513.65k)
  • Mr. Charles Huiner, Consultant (Age 49, Pay $558.46k)
  • Mr. Keith J. Sullivan, Director & Advisor to MiraDry Bus. (Age 62, Pay $40k)
  • Ms. Deborah Bettencourt, VP of HR & Corp. Admin.

What is Sientra's stock symbol?

Sientra trades on the NASDAQ under the ticker symbol "SIEN."

Who are Sientra's major shareholders?

Sientra's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Deerfield Management Company L.P. Series C (8.27%), UBS Group AG (4.82%), Mutual of America Capital Management LLC (2.62%), Goldman Sachs Group Inc. (2.49%), Assenagon Asset Management S.A. (1.00%) and HighTower Advisors LLC (0.71%). Company insiders that own Sientra stock include Jeffrey M Nugent, Keith J Sullivan, Paul Sean Little and Timothy Haines.
View institutional ownership trends for Sientra
.

Which major investors are selling Sientra stock?

SIEN stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Deerfield Management Company L.P. Series C, UBS Group AG, HighTower Advisors LLC, SG Americas Securities LLC, and Algert Global LLC.
View insider buying and selling activity for Sientra
.

Which major investors are buying Sientra stock?

SIEN stock was bought by a variety of institutional investors in the last quarter, including Mutual of America Capital Management LLC, Assenagon Asset Management S.A., Baird Financial Group Inc., California Public Employees Retirement System, State of Wisconsin Investment Board, Bank of New York Mellon Corp, Rockefeller Capital Management L.P., and Wedbush Securities Inc.. Company insiders that have bought Sientra stock in the last two years include Keith J Sullivan, and Paul Sean Little.
View insider buying and selling activity for Sientra
.

How do I buy shares of Sientra?

Shares of SIEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sientra's stock price today?

One share of SIEN stock can currently be purchased for approximately $3.96.

How big of a company is Sientra?

Sientra has a market capitalization of $199.24 million and generates $83.70 million in revenue each year. The medical instruments supplier earns $-106,820,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis. Sientra employs 339 workers across the globe.

What is Sientra's official website?

The official website for Sientra is www.sientra.com.

How can I contact Sientra?

Sientra's mailing address is 420 SOUTH FAIRVIEW AVENUE SUITE 200, SANTA BARBARA CA, 93117. The medical instruments supplier can be reached via phone at 805-562-3500 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.